10:37 AM EDT, 10/21/2024 (MT Newswires) -- LENZ Therapeutics ( LENZ ) said Monday the US Food and Drug Administration has accepted its new drug application for its LNZ100 eye drops to treat presbyopia, an age-related loss of near vision.

The FDA has assigned a prescription drug user fee act target action date of Aug. 8, 2025, for LNZ100, the company said.

The company's shares were up 2.5% in recent trading.

Price: 28.69, Change: +0.70, Percent Change: +2.48